New hope for Hard-to-Treat thyroid cancer: AL2846 shows promise in early trial

NCT ID NCT05745363

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 18 times

Summary

This study tested a new drug called AL2846 in 33 adults with a type of thyroid cancer that no longer responds to radioactive iodine or standard targeted therapies. The goal was to see if the drug could shrink tumors or slow cancer growth. Participants took the capsule daily, and researchers measured how many had their tumors shrink or stabilize. The trial is complete, and results will help decide if larger studies are needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Affiliated Hospital Of Guilin Medical University

Guilin, Guangxi, 541001, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330029, China
Yunnan Cancer Hospital

Kunming, Yunnan, 650011, China

Conditions

Explore the condition pages connected to this study.

DIFFERENTIATED THYROID CANCER